| 26.22 -0.19 (-0.72%) | 01-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 31.08 |
1-year : | 32.2 |
| Resists | First : | 26.61 |
Second : | 27.56 |
| Pivot price | 26.65 |
|||
| Supports | First : | 25.05 |
Second : | 20.84 |
| MAs | MA(5) : | 26.6 |
MA(20) : | 26.47 |
| MA(100) : | 27.62 |
MA(250) : | 27.8 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 33.8 |
D(3) : | 48.9 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 31.54 | Low : | 24.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PFE ] has closed below the lower bollinger band by 0.4%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.7 - 26.85 | 26.85 - 27.02 |
| Low: | 25.78 - 25.95 | 25.95 - 26.13 |
| Close: | 25.9 - 26.2 | 26.2 - 26.51 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Tue, 14 Jan 2025
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Tue, 14 Jan 2025
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Tue, 14 Jan 2025
Jim Cramer on Pfizer Inc. (PFE) CEO Albert Bourla: ‘President-elect Trump Felt That Bourla Was A Hero During COVID’ - Yahoo Finance
Tue, 14 Jan 2025
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges - Yahoo Finance
Tue, 14 Jan 2025
Does The Market Have A Low Tolerance For Pfizer Inc.'s (NYSE:PFE) Mixed Fundamentals? - Yahoo Finance
Mon, 13 Jan 2025
Pfizer CEO Says Activist Wants Minimal Changes, Plays Down Fight - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 5,670 (M) |
| Shares Float | 5,660 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 67.8 (%) |
| Shares Short | 85,370 (K) |
| Shares Short P.Month | 94,540 (K) |
| EPS | 0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.29 |
| Profit Margin | 7.1 % |
| Operating Margin | 32.9 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | 4.5 % |
| Qtrly Rev. Growth | 31.2 % |
| Gross Profit (p.s.) | 7.3 |
| Sales Per Share | 10.47 |
| EBITDA (p.s.) | 3.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 11,260 (M) |
| Levered Free Cash Flow | 11,420 (M) |
| PE Ratio | 34.95 |
| PEG Ratio | 0 |
| Price to Book value | 1.6 |
| Price to Sales | 2.5 |
| Price to Cash Flow | 13.2 |
| Dividend | 0.41 |
| Forward Dividend | 0 |
| Dividend Yield | 1.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|